NCT05551793Phase 2Recruiting
Regeneron AA Multicenter (Dupilumab)
Dupilumab in the Treatment of Alopecia Areata Patients With an Atopic Background and/or High IgE
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Recruiting
- Declared phase
- Phase 2
- Sponsor
- Emma Guttman
- Participants (registry)
- 76
- Start
- April 2023
- Primary completion
- November 2027 (planned)
- Study completion
- October 2028 (planned)
- Last registry update
- June 2026
- Countries
- United States
Conditions studied: Alopecia Areata
Interventions: Dupilumab, Placebo
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.